WT1 317–327 (HLA-A*01:01)

Buy 5, pay 4 If you order 5 or more of the same off-the-shelf peptide product at once, you will receive one of them for free.
€60.40 *

Prices plus VAT plus shipping costs

Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.

Amount in mg:

5 mg

  • EP11465_1
Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans.... more
Product information "WT1 317–327 (HLA-A*01:01)"

Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance. The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy. This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.

Available downloads:

 
Sequence:TSEKRPFMCAY
Gene:WT1
Delivery: 2-3 days
C-Terminus:OH
N-Terminus:H
Purity:95%
Amount:1 mg
Counter Ion:TFA
Protein:Wilms-Tumor-Protein
Species:Human
Allele:HLA-A*01:01
Application :Cellular immune response, Immune monitoring, T-cell assays, Immunohistochemistry
Indication :AIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 days
####
    Viewed
    WT1 317–327 (HLA-A*01:01)